CHECKMATE-648

NCT03143153 📎

Regimen

Experimental
nivolumab + chemo (cisplatin/5-FU); or nivolumab + ipilimumab (chemo-free)
Control
cisplatin/5-FU

Population

Previously untreated unresectable advanced, recurrent, or metastatic ESCC

Key finding

TC PD-L1>=1%: nivo+chemo mOS 15.4 vs 9.1 mo (HR 0.54); nivo+ipi mOS 13.7 vs 9.1 mo (HR 0.64); overall: nivo+chemo 13.2 vs 10.7 mo (HR 0.74); nivo+ipi 12.7 vs 10.7 mo (HR 0.78); all primary endpoints met

Source: PMID 35108470

Timeline

    Guideline citations

    • NCCN ESOPHAGEAL (p.120)